Introduction: This open-label, phase 3b study
INTRODUCTION
Opioid analgesics are recommended for managing severe, chronic low back pain [1, 2] .
Opioid treatment may be associated with side effects [3] that may be the first reason leading patients to discontinue opioid therapy [4, 5] or rotate to a different opioid. Gastrointestinal side effects, including nausea, constipation, and vomiting, are among the most commonly reported opioid-related side effects [4] , and patients have reported that these are the most bothersome side effects associated with opioid treatment [6, 7] . Patients often miss or decrease their dose of opioid analgesic or discontinue opioid treatment to avoid nausea, vomiting, and constipation [7, 8] , and physicians often discontinue opioid therapy because of these side effects [9] . In a survey [8] of 322 patients taking daily oral opioids and laxatives, 33% of patients had skipped, decreased, or stopped their opioid analgesic in order to obtain relief from opioid-induced constipation. In addition, opioid analgesics may not be effective for all patients with chronic pain, particularly patients with a neuropathic pain component to their low back pain (e.g., radiculopathy), which may not respond particularly well to opioid analgesics alone [10, 11] . Chronic therapy with opioid analgesics may result in development of tolerance, such that patients require higher average doses to maintain effective analgesia but potentially leading to more side effects [12] .
Such tolerance development is another major reason why patients require opioid rotation [12] .
The vast majority of physicians (>90%) report using combination treatment rather than monotherapy for the management of severe, chronic pain [13] ; however, a recent Cochrane review by Chaparro and colleagues [14] of randomized controlled trials evaluating combination therapy for neuropathic pain found that although combination therapy offered similar or sometimes a modest gain in efficacy, it was often associated with higher incidences of side effects and discontinuations due to side effects.
The centrally acting analgesic tapentadol has two mechanisms of action, µ-opioid receptor agonism and noradrenaline reuptake inhibition [15, 16] . Tapentadol has been shown to be effective and well tolerated for the management of moderate to severe, chronic pain in previous phase 3 studies [17−21] , including randomized, doubleblind, placebo-controlled studies in patients with low back pain [18] and pain related to diabetic peripheral neuropathy [20] . A pooled analysis [19] were not a main objective of the trial, but were captured and are described here. Equianalgesic ratios were determined for tapentadol versus WHO step III analgesics, including analgesics other than oxycodone, which has been the primary active comparator during clinical trials evaluating tapentadol. Informed consent was obtained from all patients for inclusion in the study.
MATERIALS AND METHODS

All
Patient Population
This study included men and nonpregnant, nonlactating women who were at least 18 years of age and had a diagnosis of chronic low back pain that had been present for a minimum of responded to that analgesic, as indicated by an average pain intensity score at screening of no more than 5 on an 11-point numerical rating scale-3 (NRS-3; average pain intensity [11-point NRS; 0 = "no pain" to 10 = "pain as bad as you can imagine"] over the 3 days prior to the pain intensity assessment). Eligible patients had to report opioid-related side effects as the reason for a change in their analgesic, and subject satisfaction with their previous treatment was not permitted to be better than "fair" on a 5-point verbal rating scale (VRS; 0 = "poor," 1 = "fair," 2 = "good," 3 = "very good," 4 = "excellent").
Patients were excluded from the study if they had any concomitant painful conditions other than low back pain (e.g., anatomical deformities, fibromyalgia), had any clinically significant disease or laboratory finding, had active systemic or local infection, or required any painful procedures during the study (e.g., major surgery) that could confound or bias study assessments. to the previous analgesic regimen, as indicated by a pain intensity score (11-point NRS-3) that was the same or lower than at baseline. Doses could then be titrated to achieve (or exceed) the following goals: at least a 1-point reduction in the pain intensity score from baseline and a subject satisfaction with treatment rating (5-point VRS) of at least "good."
Unless patients were participating in a tapering substudy (described below), doses of WHO step I analgesics and coanalgesics and medications used to control opioid-related side effects due to the previous analgesic regimen were kept stable throughout the titration and maintenance periods. During the titration period and the remainder of the study, tapentadol immediate release [IR] was permitted in doses of 50 mg up to twice a day and at least 4 h apart for acute pain episodes due to index pain that had no clear cause, was related to increased activity or movement (incidental pain), or was related to end-of-dose failure (which indicated a need to adjust the dose of tapentadol PR) and for withdrawal symptoms, such as hyperalgesia, that might occur during the first days of the titration period after stopping treatment with the previous opioid and that were related to the previous opioid. Patients were not permitted to take combined TDD of tapentadol PR and tapentadol IR of more than 500 mg per day.
The dose of tapentadol PR determined during the titration period was continued during the maintenance period. 
Effectiveness, Function, Quality of Life, and
Tolerability Evaluations
Safety and tolerability analyses were performed on all patients who took one or more doses of study medication (the safety population). The pain intensity, responder rate, and equianalgesic analyses described in this section were performed for both the main analysis and per-protocol populations; all other effectiveness, function, and quality-of-life analyses were performed only for the main analysis population. The main analysis population included all patients who took one or more doses of study medication and had one or more post-baseline pain intensity assessments, and the per-protocol population (which was a subset of the main analysis population) included all patients who had received treatment through week 6 and had no major protocol deviations.
Patients rated their pain intensity (11-point NRS-3) at screening, baseline, and all subsequent study visits. The primary endpoint for this study was responder rate 1 at week 6 in the perprotocol population, using the last observation carried forward (LOCF) to impute missing assessments; responder rate 1 was defined as the percentage of patients with the same or a lower pain intensity score compared with week −1 (when patients were on their previous WHO step III opioid). Responder rate 2 at week 6 (LOCF) in the per-protocol population was used as a secondary endpoint; responder rate 2 was defined as the percentage of patients with the same or a lower pain intensity score and an improvement in subject satisfaction with treatment of one category or more. Responder rates 1 and 2 were also analyzed in the main analysis population using observed-case analysis at weeks 6, 8, and 12. The following assessments were also evaluated as secondary endpoints: the change in average pain intensity from week −1 to weeks 6, 8, and 12; subject satisfaction with prior treatment (at screening and baseline) and study treatment (at the interim visit and all subsequent study visits; 5-point VRS); the patient global impression of change (PGIC) [23, 24] , the clinician global impression of change (CGIC) [25] , the EuroQol-5 Dimension (EQ-5D) health status questionnaire [26] , the Short Form-36 (SF-36) health survey [27] , and the Hospital Anxiety and Depression Scale (HADS) [28] .
For the PGIC [23, 24] and CGIC [25] , patients and investigators, respectively, rated their impression of the change in the patients' overall condition since baseline using a 7-point numerical rating scale (1 = "very much improved" to 7 = "very much worse"). Both the PGIC and CGIC were completed at the interim visit and all subsequent study visits. For the EQ-5D health status questionnaire [26] , patients rated five dimensions of health status (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using one of three possible levels ("no problems," "some problems,"
or "extreme problems"). The SF-36 health status questionnaire [27] was used to assess eight different dimensions of health status (physical activities, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health); each of the eight dimensions was scored on a scale from 0 ("poor health") to 100 ("good health"). For the HADS (used to assess anxiety and depression in medically compromised patients) [28] , patients rated 14 questions that assessed different aspects of anxiety and depression on a 4-point scale (0−3), with higher scores indicating more severe anxiety or depression symptoms [29] . The EQ-5D health status questionnaire, the SF-36 health status questionnaire, and the HADS were completed at screening, baseline, week 1, and at each study visit from week 5 through week 12. 
Neuropathic Pain Component Evaluations
The likelihood of a neuropathic pain component to low back pain was evaluated using the painDETECT questionnaire [30] , which is a validated and highly sensitive screening tool that addresses the frequency and quality of neuropathic pain symptoms (seven items), pain patterns over time (one item), and radiating pain (one item). Scores for those nine items were summed to yield a total painDETECT score 
Statistical Analyses
It was estimated that approximately 70% of the total study population would be eligible for inclusion in the per-protocol population.
An estimated 125 patients in the per-protocol population would provide 80% power to differentiate between a responder rate 1 at week 6 of at least 60% and the null hypothesis responder rate 1 of less than 60%, with a noninferiority margin of 14.3. For responder rate 2, it was estimated that 125 patients in the per-protocol population would provide 80% power to differentiate between a responder rate 2 at week 6 of at least 60% and the null hypothesis responder rate 2 of less than 60%, with a noninferiority margin of 14.3%. An estimated 125 patients in the per-protocol population would provide 80% power to reject the null hypothesis that the average pain intensity score at week −1 was not equivalent to that at week 6 (i.e., the difference in means was ≥0.673 or farther away from 0 in the same direction), in favor of the alternative hypothesis that responder rate 1 was at least 60% (i.e., tapentadol PR provided noninferior analgesia relative to the previous WHO step III treatment).
Given the rejection of the null hypothesis at the first two steps, it was estimated that a study population of 178 patients would provide 80% power to perform the described analyses of responder rate 1, responder rate 2, and pain intensity in a step-wise manner.
The primary endpoint (responder rate 1 at week 6 in the per-protocol population using the LOCF) was evaluated using a 1-sided Chi-square test, as were responder rate 2 at week 6 in the 
RESULTS
Patients
This study was prematurely terminated due to slow recruitment and study drug shortages; as a result, the numbers of patients in the study populations were lower than initially planned. A total of 125 patients were included in the safety population, 123 patients were included in the main analysis population, and 94 patients were Table 2 , and the history of low back pain is summarized in Table 3 a Baseline painDETECT classi cations were based on the total painDETECT score (possible score, 0−38); the likelihood of a neuropathic pain component to low back pain was classi ed as "negative" (score of 0−12), "unclear" (score of 13−18), or "positive" (score of 19−38) multiple previous analgesic regimens and a high degree of suffering, particularly for those with a neuropathic pain component. Fig. 2) .
On the PGIC, the percentage of patients who reported that their overall status was "minimally improved," "much improved," or "very much improved" since starting study treatment was 79.4% (81/102) at week 6, 83.3% (80/96) at week 8, and 87.1% (81/93) at week 12 (Fig. 3) .
On the CGIC, a rating of "minimally improved," "much improved," or "very much improved" for the patients' overall status since starting study 
Treatment Exposure and Equianalgesia to
Prior WHO Step III Opioids Table 6 shows the number of dose adjustments required to reach the minimum target of tapentadol PR at week 6 is described in Table 7 .
Equianalgesic ratios for tapentadol PR alone to PR formulations of oral oxycodone, transdermal buprenorphine, transdermal fentanyl, oral morphine, and oral hydromorphone are summarized in Table 8 (Table 9) .
Neuropathic Pain Component
Significant decreases from baseline were shown in the mean (SD) total painDETECT score at weeks 6, 8, and 12 in the painDETECT e minimum target of titration was de ned as achieving at least similar e cacy compared to the previous treatment (i.e., pain intensity score [11-point numerical rating scale-3] that was the same or lower than at baseline) b Based on the primary endpoint responder rate 1 analysis Table A8 ). Improvements in NPSI results were consistent at weeks 6 and 12
whether LOCF or no imputation method was used (Appendix Table A8 ).
Tapering Substudy
Overall (Table 12 ). All patients (n = 6) who were tapering their dose of WHO step I analgesics during the substudy completely stopped their WHO step I analgesic doses (Table 12 ). The WHO step I analgesics reduced in the substudy included diclofenac sodium, ketoprofen, and paracetamol; the coanalgesics reduced in substudy A included amitriptyline, duloxetine, gabapentin, pregabalin, tolperisone, 
Safety and Tolerability
All patients reported at least one NTEAE. Of NPSI Neuropathic Pain Symptom Inventory, SD standard deviation a n = 69 b n = 60 * P < 0.05 for the change from baseline were classified as at least possibly related to study medication. A total of 78.6% (286/364) of the reported TEAEs were of mild-to-moderate intensity. The TEAEs that were reported by at least 5% of patients are summarized in Table 13 . [33] , it was not validated when this study was conducted [30] . Therefore, the validated NPSI [31] For patients showing a poor response to an opioid analgesic or who experience intolerable side effects, opioid switching is often used to improve pain relief or tolerability [37, 38] .
Determining the appropriate ratio, when switching from one opioid analgesic to another, is critical for successful conversion, particularly for patients who showed a poor response to the prior opioid or for those who are switching from high doses of opioids [37] . Drug overdose may result in intolerable side effects with the new opioid analgesic, while underdosing may result in the occurrence of withdrawal symptoms.
In a study of patients with chronic, nonmalignant pain, the rate of withdrawal was 32% for patients switching from one PR opioid to another and 44% for patients switching from an IR opioid to a PR opioid [39] . There is a lack of strong evidence related to opioid switching, particularly with respect to adequate equipotency data [37, 38] . 
CONCLUSIONS
Results of this open-label, phase 3b study support those of previous, randomized, doubleblind, controlled, phase 3 studies of tapentadol PR for moderate-to-severe, chronic low back pain [18] and neuropathic pain (painful diabetic peripheral neuropathy) [20] . Overall, results indicate that direct rotation from previous WHO step III opioid therapy to tapentadol PR could be achieved without compromising pain relief in a strong opioid responder population, allowing for even further reduction of pain intensity.
Equianalgesic ratios could be calculated in the current study for tapentadol to oxycodone, buprenorphine, fentanyl, morphine, and hydromorphone; the equianalgesic ratios calculated for tapentadol to oxycodone were in line with those observed in previous randomized, double-blind, placebo-and activecontrolled, phase 3 studies of tapentadol PR for chronic pain, in which oxycodone was the main comparator [17, 18] . Table A1 Responder rates 1 and 2 at baseline and at weeks 6 and 12 using observed-case analysis (with and without the week 9−12 data for the tapering substudy population) and using the LOCF (without the week 9−12 data for the tapering substudy population) -main analysis population LOCF last observation carried forward, NRS-3 numerical rating scale-3, SD standard deviation. * P < 0.05 for the change from baseline Table A3 Subject satisfaction with treatment ratings at baseline and at weeks 6 and 12 using observed-case analysis (with and without the week 9-12 data for the tapering substudy population) and using the LOCF (without the week 9-12 data for the tapering substudy population) -main analysis population Table A4 PGIC and CGIC ratings at baseline and at weeks 6 and 12 using observed-case analysis (with and without the week 9-12 data for the tapering substudy population) and using the LOCF (without the week 9-12 data for the tapering substudy population) -main analysis population EQ-5D EuroQol-5 Dimension, LOCF last observation carried forward, SD standard deviation *P < 0.0001 for the change from baseline Table A6 Mean (SD) SF-36 scores at baseline and at weeks 6 and 12 using observed-case analysis (with and without the week 9-12 data for the tapering substudy population) and using the LOCF (without the week 9-12 data for the tapering substudy population) -main analysis population BL, n = 119; observed-case analysis: W6, n = 99; W12 (with substudy), n = 92; W12 (without substudy), n = 69; LOCF: W6, n = 118; W12 (without substudy), n = 95 b BL, n = 120; observed-case analysis: W6, n = 101; W12 (with substudy), n = 93; W12 (without substudy), n = 70; LOCF: W6, n = 118; W12 (without substudy), n = 95 c BL, n = 120; observed-case analysis: W6, n = 100; W12 (with substudy), n = 93; W12 (without substudy), n = 70; LOCF: W6, n = 118; W12 (without substudy), n = 95 * P < 0.05 for the change from baseline Table A7 Mean (SD) HADS anxiety and depression subscale scores at baseline and at weeks 6 and 12 using observed-case analysis (with and without the week 9-12 data for the tapering substudy population) and using the LOCF (without the week 9-12 data for the tapering substudy population) -main analysis population With Without Without Number of pain attacks substudy substudy substudy during the past 24 h, n (%) (n = 76) (n = 65) (n = 59) (n = 42) (n = 74) (n = 57)
APPENDIX
